Sign up to save your podcasts
Or
Share Lepodisiran Phase I Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lepodisiran Phase I Trial
Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).
View all episodes
By TCTMD
4
22 ratings
Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).
More shows like Talking Points
View all
NEJM This Week
328 Listeners
JAMA Clinical Reviews
500 Listeners
JACC This Week
167 Listeners
This Week in Cardiology
910 Listeners
Heart Sounds Podcast
12 Listeners
The Curbsiders Internal Medicine Podcast
3,384 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
730 Listeners
Annals On Call Podcast
197 Listeners
JAMA Medical News
90 Listeners
The Clinical Problem Solvers
517 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
362 Listeners
Cardionerds: A Cardiology Podcast
436 Listeners
Critical Care Time
271 Listeners